🔷 The approval strengthens precision oncology by supporting more personalized treatment decisions in upper gastrointestinal cancers. PD-L1 testing remains a key tool in optimizing therapy selection and improving clinical outcomes.
🔗 Read more: bit.ly/ONCOnews-23-...
#ONCOnews #OncoAlert #OncEd
🔷 Relacorilant, a selective glucocorticoid receptor antagonist, enhances chemotherapy activity through cortisol pathway modulation, offering a promising new approach for patients with limited therapeutic alternatives.
🔗 Read more: bit.ly/ONCOnews-27M...
#ONCOnews #OncoAlert #OncEd #FDAApproval
🔷 Fast Track status may support expedited development and regulatory review of TRI-611. This milestone reflects continued progress in expanding targeted therapy options for patients with ALK-driven tumors.
🔗 Read more: bit.ly/ONCOnews-26-...
#ONCOnews #OncoAlert #OncEd #LungCancer #NSCLC
🔷 The combination significantly improved 3-year DFS (86.3% vs 76.2%; HR 0.50; P<0.001), with higher grade 3–4 adverse events (84.1% vs 71.9%); overall survival remains a secondary endpoint under evaluation.
🔗 Read more: bit.ly/ONCOnews-26-...
#ONCOnews #OncoAlert #OncEd #Oncology #CancerResearch
🔷 Orphan Drug Designation supports accelerated development in high unmet-need settings, underscoring growing interest in targeted ADC approaches to improve outcomes in this aggressive malignancy.
🔗 Read more: bit.ly/ONCOnews-25-...
#ONCOnews #OncoAlert #OncEd #Oncology #CancerResearch #LungCancer
🔷 Phase 3 SWOG 1826 data showed significantly improved progression-free survival with nivolumab + AVD (HR 0.42; 58% risk reduction), supporting its role in advancing long-term disease control.
🔗 Read more: bit.ly/ONCOnews-24M...
#ONCOnews #OncoAlert #OncEd #Oncology #Hematology #HodgkinLymphoma
🔷 The combination significantly improved radiographic progression-free survival versus Enzalutamide alone, exceeding the predefined hazard ratio target of 0.63, with consistent benefit across BRCA and non-BRCA subgroups
🔗 Read more: bit.ly/ONCOnews-23-...
#ONCOnews #OncoAlert #OncEd #Prostate
🔷 Relapsed/refractory DLBCL remains a challenging setting with limited durable treatment options for many patients. The Phase III development of HMPL-760 may contribute to expanding targeted therapy strategies in aggressive lymphoma.
🔗 Read more: bit.ly/ONCOnews-23-...
#ONCOnews #OncoAlert #OncEd
🔷 Findings from BRIGHT-2 provide important insights into combination therapy approaches for HR+ advanced breast cancer following endocrine progression.
🔗 Read more: bit.ly/ONCOnews-23-...
#ONCOnews #OncoAlert #OncEd #BreastCancer #AdvancedBreastCancer #HRPositive #Oncology #CancerResearch
🔗 Read more: bit.ly/ONCOnews-19M...
#ONCOnews #OncoAlert #OncEd #OvarianCancer #CancerResearch #Oncology #PrecisionMedicine #PersonalizedMedicine #CompanionDiagnostics #Biomarkers #TargetedTherapy #CancerCare #OncologyNews #ClinicalTrials #DrugDevelopment #FDAApproval #PharmaNews #MedTech
🔷 With a median follow-up of 5.5 years, three-year EFS was 59% with zoledronic acid vs 57% without, while OS was 75% in both groups. These results showed no survival benefit from adding zoledronic acid.
🔗 Read more: bit.ly/ONCOnews-16-...
#ONCOnews #OncoAlert #OncEd #Oncology #CancerResearch
🔗 Read more: bit.ly/ONCOnews-16-...
#ONCOnews #OncoAlert #OncEd #Oncology #CancerResearch #CervicalCancer #Immunotherapy #CancerTreatment #ClinicalTrials #OncologyNews #MedicalResearch #PrecisionMedicine #CancerCare #HealthcareInnovation #CancerScience #OncologyCommunity #WomenHealth #Gynecologic
🔷 However, the combination did not improve overall survival (OS) (15.0 vs 17.9 months; HR 1.15) and was associated with higher grade 3–4 adverse events (66.9% vs 38.3%).
🔗 Read more: bit.ly/ONCOnews13-M...
#ONCOnews #OncoAlert #OncEd #Oncology #CancerResearch #Immunotherapy #TargetedTherapy
🔷 84% of patients receiving Romiplostim avoided CIT-related chemotherapy delays or dose reductions vs 36% with placebo (OR 10.16, P<0.001).
🔗 Read more: bit.ly/ONCOnews-12M...
#ONCOnews #OncoAlert #OncEd #Chemotherapy #Thrombocytopenia #ChemotherapyInducedThrombocytopenia #Oncology #Cancer
🔷 If cleared, the system could improve surgical accuracy and potentially reduce the need for repeat procedures. Innovations like this aim to enhance outcomes and support more effective breast-conserving surgery.
🔗 Read more: bit.ly/ONCOnews-12M...
#ONCOnews #OncoAlert #OncEd #BreastCancer #Breast
🔷 Findings highlight how advanced imaging may refine prognosis and guide more personalized treatment strategies in prostate cancer.
🔗 Read more: bit.ly/ONCOnews-11M...
#ONCOnews #OncoAlert #OncEd #ProstateCancer #PSMAPET #Oncology #CancerResearch #CancerImaging #PrecisionMedicine #Urology #Cancer
🔷 The study explores whether this combination strategy can offer improved clinical outcomes compared with standard immunotherapy alone.
🔗 Read more: bit.ly/ONCOnews-11M...
#ONCOnews #OncoAlert #OncEd #LungCancer #NSCLC #CancerResearch #Oncology #Immunotherapy #CancerTreatment #ClinicalTrials
🔷 This marks the first positive Phase III trial for the oral CELMoD Mezigdomide, with a safety profile consistent with prior studies.
🔗 Read more: bit.ly/ONCOnews10Ma...
#ONCOnews #OncoAlert #OncEd #MultipleMyeloma #Hematology #Oncology #CancerResearch #ClinicalTrials #Phase3Trial
🔗 Read more: bit.ly/ONCOnews09Ma...
#ONCOnews #OncoAlert #OncEd #BreastCancer #TrastuzumabDeruxtecan #AntibodyDrugConjugate #ADC #CancerTreatment #Oncology #OncologyNews
🔷 Development of Giredestrant continues across settings, including evERA in advanced disease (NDA accepted by the FDA) and lidERA in early breast cancer, with submission planned soon.
🔗 Read more: bit.ly/ONCOnews09Ma...
#ONCOnews #OncoAlert #OncEd #BreastCancer #AdvancedBreastCancer #Metastatic
🔷 Based on the MajesTEC-3 trial, this combination brings together a BCMA-targeted bispecific antibody and CD38-directed therapy, offering a novel dual-targeted approach for patients who have received prior lines of therapy.
🔗 Read more: bit.ly/ONCOnews06-M...
#ONCOnews #OncoAlert #OncEd #Oncology
🔷 Based on results from the phase 3 BRUIN CLL-321 trial, this treatment expands options for patients progressing after prior BTK inhibitor therapy, marking a key milestone in hematologic oncology.
🔗 Read more: bit.ly/ONCOnews04-M...
#ONCOnews #OncoAlert #OncEd #Oncology #CancerCare #Cancer
🔷 Based on Phase 3 VERIFY data, if approved, Rusfertide could become a first-in-class therapy, offering a novel treatment approach for patients requiring improved hematocrit control.
🔗 Read more: bit.ly/ONCOnews03-M...
#ONCOnews #OncoAlert #OncEd #BiotechNews #PharmaNews #Oncology #Hematology
🔷 The LITESPARK-022 Phase 3 data suggests added benefit from combining PD-1 blockade with HIF-2α inhibition in the post-nephrectomy setting.
🔗 Read more: bit.ly/ONCOnews02-M...
#ONCOnews #OncoAlert #OncEd #Oncology #CancerResearch #Immunotherapy #TargetedTherapy #RenalCellCarcinoma #KidneyCancer
🔷 This regulatory milestone underscores continued progress in targeted therapies for lung cancer and reinforces momentum in precision oncology.
🔗 Read more: bit.ly/ONCOnews27Fe...
#ONCOnews #OncoAlert #OncEd #Oncology #CancerCare #Healthcare #Medicine #Innovation #Science #MedicalResearch #Pharma
🔷 The findings signal a potential new therapeutic option for patients with limited treatment choices in advanced TNBC.
🔗 Read more: bit.ly/ONCOnews27Fe...
#ONCOnews #OncoAlert #OncEd #Oncology #CancerCare #Healthcare #Medicine #Innovation #Science #Oncology #CancerResearch #HealthTech
🔷 These findings reinforce the value of a bone-targeted combination strategy in improving outcomes for patients with advanced, high-risk disease.
🔗 Read more: bit.ly/ONCOnews27Fe...
#ONCOnews #OncoAlert #OncEd #Oncology #CancerCare #Healthcare #Medicine #Innovation #Science #MedicalResearch
🔷 This approval bolsters biomarker-driven strategies in first-line metastatic colorectal cancer, giving clinicians a new evidence-based option to improve patient outcomes.
🔗 Read more: bit.ly/ONCOnews25Fe...
#ONCOnews #OncoAlert #OncEd #Oncology #CancerCare #ColorectalCancer #mCRC #Cancer
🔷 Findings from the randomized, double-blind study led by GETNE provide important evidence on the role of adding targeted therapy to Somatostatin analogs in progressive NET management.
🔗 Read more: bit.ly/ONCOnews23Fe...
#ONCOnews #OncoAlert #OncEd #NeuroendocrineTumors #NETs #Oncology #Cancer
🔷 This first all-oral, fixed-duration (14 cycles), chemo-free regimen reduced progression/death risk by 35% vs.chemoimmunotherapy in the AMPLIFY study (HR 0.65; p=0.0038)
🔗 Read more: bit.ly/ONCOnews23Fe...
#ONCOnews #OncoAlert #OncEd #FDAApproval #CLL #Leukemia #Hematology #Oncology #Cancer
